Memo Therapeutics AG reposted this
🎉 🎉 🎉 A huge thank you to everyone involved for getting our Series C Extension over the finish line! To name a few: 💉 New investors: Thomas Harth (Ysios Capital), Hadrien Bouchez (Kurma Partners) 💉 Existing investors: Veronica Gambillara Fonck (Pureos Bioventures), Robert Schier (Swisscanto), Philippe Dro (Adjuvant Capital), Christian Schneider (Vesalius Biocapital III) 💉 Legal: Oliver Gnehm (BGPartner | Attorneys-at-law), Matthias Staehelin (Vischer) The incremental funds will be used to expand Phase II of our best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation. Initial data from the Phase II trial is expected in the first half of 2025. #Transplantation #Nephrology https://lnkd.in/dRsEr7g3
